We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+30.25%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12B
AUM Growth
+$2.23B
Cap. Flow
-$2.3B
Cap. Flow %
-19.15%
Top 10 Hldgs %
76.74%
Holding
140
New
18
Increased
23
Reduced
51
Closed
10

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$121M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$106M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$76.4M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51.5M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$34.6M

Top Sells

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$653M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$73M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$30.8M
4
PCYC
PHARMACYCLICS INC
PCYC
+$17.3M
5
XOMA
Xoma
XOMA
+$8.13M

Sector Composition

Rank Sector Weight
1 Healthcare 40.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DERM
101
DELISTED
Dermira, Inc.
DERM
$1.53M 0.01%
100,000
– –
OSUR icon
102
OraSure Technologies
OSUR
$274M
$1.5M 0.01%
229,397
-5,267
-2% -$43.7K
ALDX icon
103
Aldeyra Therapeutics
ALDX
$97.1M
$1.45M 0.01%
+142,000
New +$1.45M
RIGL icon
104
Rigel Pharmaceuticals
RIGL
$723M
$1.27M 0.01%
35,719
-12,478
-26% -$342K
LOXO
105
DELISTED
Loxo Oncology, Inc
LOXO
$1.25M 0.01%
100,000
– –
ALNY icon
106
Alnylam Pharmaceuticals
ALNY
$38.3B
$1.18M 0.01%
11,340
-260
-2% -$26.3K
XLRN
107
DELISTED
Acceleron Pharma
XLRN
$1.09M 0.01%
28,765
– –
AKAO
108
DELISTED
Achaogen Inc
AKAO
$976K 0.01%
100,000
– –
MDGL icon
109
Madrigal Pharmaceuticals
MDGL
$12.6B
$949K 0.01%
13,973
-313
-2% -$26.8K
NBSE
110
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$941K 0.01%
+926
New +$3.06M
QURE icon
111
uniQure
QURE
$2.75B
$730K 0.01%
30,000
-672
-2% -$14.7K
FPRX
112
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$440K ﹤0.01%
19,247
-576
-3% -$14.5K
AEGR
113
DELISTED
Aegerion Pharmaceuticals
AEGR
$374K ﹤0.01%
+14,300
New +$364K
CCXI
114
DELISTED
ChemoCentryx, Inc.
CCXI
$370K ﹤0.01%
49,064
-936
-2% -$7.31K
APTO
115
DELISTED
Aptose Biosciences, Inc.
APTO
$181K ﹤0.01%
74
-991
-93% -$2.39M
BTX.WS
116
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$40K ﹤0.01%
20,084
-441
-2% -$591
ALBO
117
DELISTED
Albireo Pharma Inc
ALBO
$36K ﹤0.01%
+1,006
New +$42.4K
AKTX
118
Akari Therapeutics
AKTX
$14.4M
– –
-84
Closed -$3.23M
FOLD
119
DELISTED
Amicus Therapeutics
FOLD
– –
-481,697
Closed -$4.01M
GERN icon
120
Geron
GERN
$911M
– –
-402,629
Closed -$1.31M
MNK
121
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-46,666
Closed -$4.62M
SGYP
122
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-973,245
Closed -$2.97M
TSRO
123
DELISTED
TESARO, Inc.
TSRO
– –
-31,218
Closed -$1.16M
QLTI
124
DELISTED
QLT Inc
QLTI
– –
-1,535,863
Closed -$6.16M
SLXP
125
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
– –
-635,321
Closed -$73M
2 3 4
5
6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2015 Portfolio in Review

As of Q1 2015, Baker Bros. Advisors held 140 positions worth $12B, up 23% from $9.8B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Baker Bros. Advisors withdrew a net $2.3B in Q1 2015, closing 10 positions and reducing 51 holdings. Its most notable exit was AVANIR PHARMACEUTICALS, INC CL A, an estimated $653M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 42% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Invitae Corporation worth $110M.

  • Baker Bros. Advisors's largest Q1 2015 buy was Invitae Corporation: 6,554,967 shares worth $110M.
  • Baker Bros. Advisors added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2015, an estimated $106M increase.
  • Baker Bros. Advisors's biggest Q1 2015 reduction was Vanda Pharmaceuticals, cutting an estimated $30.8M.
  • Baker Bros. Advisors fully exited AVANIR PHARMACEUTICALS, INC CL A in Q1 2015, selling an estimated $653M.
  • Baker Bros. Advisors's ten largest holdings make up 77% of its $12B portfolio in Q1 2015.
  • Baker Bros. Advisors opened 18 new positions and closed 10 in Q1 2015.
  • Baker Bros. Advisors's portfolio value rose 23% quarter-over-quarter to $12B.

Based on Baker Bros. Advisors's 13F filing for Q1 2015, filed 15 May 2015.